Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective

Hardik Mody(Kaiser Permanente South San Francisco Medical Center), Vijay Upreti(Amgen (United States)), Jochem Gokemeijer(Bristol-Myers Squibb (Germany)), Nagendra Chemuturi(Moderna Therapeutics (United States)), Vibha Jawa(EpiVax (United States)), Prathap Nagaraja Shastri(Springhouse), Sreeneeranj Kasichayanula(Gilead Sciences (United States)), Michael Z. Liao(Kaiser Permanente South San Francisco Medical Center), K. OGASAWARA(Bristol-Myers Squibb (United States)), Dale Miles(Kaiser Permanente South San Francisco Medical Center), Tong‐Yuan Yang(Johnson & Johnson (United States)), Xu Zhu(AstraZeneca (Brazil)), Swati Gupta(AbbVie (United States))
Clinical Pharmacology & Therapeutics
July 2, 2023
10.1002/cpt.2986
Cited by 26

Related Papers

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
|Journal of Clinical Oncology|2023|94
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)
|Bioanalysis|2021|60
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
|mAbs|2021|57
2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays)
|Bioanalysis|2018|53